Tredje AP fonden Takes $5.62 Million Position in Medpace Holdings, Inc. $MEDP

Tredje AP fonden bought a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 10,000 shares of the company’s stock, valued at approximately $5,616,000.

Other large investors also recently bought and sold shares of the company. Optiver Holding B.V. purchased a new stake in shares of Medpace in the 3rd quarter worth about $27,000. Geneos Wealth Management Inc. lifted its position in shares of Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after acquiring an additional 37 shares in the last quarter. Steigerwald Gordon & Koch Inc. acquired a new stake in shares of Medpace during the fourth quarter valued at $30,000. Elyxium Wealth LLC acquired a new position in shares of Medpace in the 4th quarter valued at about $30,000. Finally, Quarry LP purchased a new stake in shares of Medpace during the 3rd quarter worth about $35,000. Institutional investors and hedge funds own 77.98% of the company’s stock.

Insider Activity

In other news, President Jesse J. Geiger sold 31,707 shares of the company’s stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $455.30, for a total transaction of $14,436,197.10. Following the completion of the sale, the president owned 15,000 shares in the company, valued at approximately $6,829,500. This represents a 67.88% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 20.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have issued reports on MEDP. TD Cowen upgraded shares of Medpace from a “sell” rating to a “hold” rating and decreased their price objective for the stock from $462.00 to $419.00 in a research note on Wednesday, February 18th. Jefferies Financial Group upgraded shares of Medpace from a “hold” rating to a “buy” rating and set a $560.00 target price on the stock in a report on Friday, February 13th. Leerink Partners decreased their price target on shares of Medpace from $575.00 to $485.00 and set a “market perform” rating for the company in a research report on Wednesday, February 11th. Weiss Ratings lowered Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, April 6th. Finally, Wall Street Zen lowered Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Four equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $467.08.

Key Stories Impacting Medpace

Here are the key news stories impacting Medpace this week:

• Negative Sentiment: Several firms, including Pomerantz, Bronstein Gewirtz & Grossman, The Schall Law Firm, Faruqi & Faruqi, Levi & Korsinsky, and Rosen Law Firm, highlighted the class action and urged investors with losses to seek lead-plaintiff status before June deadlines, keeping legal overhang in focus for MEDP. Article title
• Negative Sentiment: One notice specifically pointed to allegations that Medpace understated cancellation rates and overstated book-to-bill strength, reinforcing concerns about the company’s operating visibility and disclosure practices. Article title
• Neutral Sentiment: Medpace shareholders also approved governance changes enhancing voting rights at the company’s annual meeting, but the update appears unlikely to offset the immediate legal concerns driving sentiment in the stock. Article title

Medpace Stock Performance

Shares of NASDAQ:MEDP opened at $419.91 on Wednesday. The company has a market cap of $11.99 billion, a PE ratio of 26.39, a price-to-earnings-growth ratio of 2.13 and a beta of 1.19. The firm has a 50 day simple moving average of $461.69 and a 200 day simple moving average of $522.27. Medpace Holdings, Inc. has a 52 week low of $287.17 and a 52 week high of $628.92.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Wednesday, April 22nd. The company reported $4.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.74 by $0.54. The business had revenue of $706.60 million during the quarter, compared to analyst estimates of $697.82 million. Medpace had a net margin of 17.19% and a return on equity of 120.89%. Medpace’s quarterly revenue was up 26.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, equities analysts predict that Medpace Holdings, Inc. will post 17.04 earnings per share for the current year.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.